argenx SEARGX -0.60%73 EBIT per Share is $22.75 as of Mar. 2026. GuruFocus rates ARGX with a GF Score™ of 73/100 and a GF Value™ of $1,407.83 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,172 Biotechnology companies, argenx SE ranks worse than 85324.15% on this metric.
argenx SE's EBIT per Share for the
three
months ended in Mar. 2026 was $6.44.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $22.75.
During the past 12 months, the average EBIT per Share Growth Rate of argenx SE was 471.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for argenx SE's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of argenx SE was 65.30% per year. The lowest was -109.60% per year. And the median was -36.30% per year.
ARGX's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
argenx SE's EBIT for the
three
months ended in Mar. 2026 was $427 Mil.
argenx SE (NAS:ARGX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
argenx SE EBIT per Share Related Terms
argenx SE EBIT per Share Historical Data
* Premium members only.
The historical data trend for argenx SE's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.75
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a EBIT per Share of $22.75 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #999999 out of 1172 companies in the Biotechnology industry.
Is argenx SE's EBIT per Share too high?
argenx SE's current EBIT per Share is $22.75. The Biotechnology industry median EBIT per Share is 15.40. argenx SE's value of $22.75 is 47.7% above this industry median. Based on the distribution chart, argenx SE ranks #999999 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, argenx SE has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #999999 out of 1172 companies for EBIT per Share. This places argenx SE in the lower half of its industry. The industry median EBIT per Share is 15.40. argenx SE's value of $22.75 is 47.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current EBIT per Share of $22.75 is 47.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current EBIT per Share is $22.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,407.83, compared to a current price of $909.49 — trading 35.4% below its estimated fair value. The current EBIT per Share is $22.75 and 47.7% above the Biotechnology industry median of 15.40. argenx SE's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For argenx SE (ARGX), the current EBIT per Share is $22.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $909.49 is trading 35.4% below its estimated GF Value™ of $1,407.83.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
EBIT per Share: $22.75
GF Value™: $1,407.83 vs. price of $909.49 (35.4% below fair value)
Industry Position: 47.7% above the Biotechnology median (#999999 of 1172)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
73GF Score
Get the complete analysis for ARGX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
